TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: modification of amplitude of the background noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of FVC/FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Knowledge, Attitudes and Practices regarding tobacco
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: dyadic coping
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Calorie Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tendon Structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental Cost-Effectiveness ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: WHO Well-Being Index (WHO-5)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in uPAR PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety/overall frequency of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety/dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Antitumor activity as measured by the objective response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fugl Meyer for lower limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perimenstrual Change in Daily Adult Suicidal Ideation Questionnaire (ASIQ) Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perimenstrual Change in Daily Columbia Suicide Severity Rating Scale (C-SSRS) Screening Interview Planning Item Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HPV-16 and/or HPV-18 negative conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: inflammatory markers assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stool frequency assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: The Ulcerative Colitis Colonoscopic Index of Severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic variability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiovascular disease risk factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of participants abstinent from alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of symptomatic Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fluency tasks from NIH Examiner
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ARENA Spatial Navigation Memory Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait Stride Length Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial Glycaemia (iAUC 0-60min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulinaemia (iAUC 0-60min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax for amodiaquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtlast for amodiaquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf for amodiaquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-8h (triglyceride)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body height and weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Television viewing (child outcomes)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Score on short Acculturation Scale (parent outcome)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Flow mediated dilation (FMD) of the brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in structural and functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 3-day bladder diary change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of participants who have experienced the death of a friend or relative
Endpoint domain: Mortality/survival
Primary endpoint: Coping efficacy scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Meaning-making scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complicated bereavement scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma metformin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Serum Concentration (Cmax) of Sarilumab at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration Versus Time Curve (AUC0-t) of Sarilumab at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration Before Treatment Administration (Ctrough) of Sarilumab at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limits of Stability Test Protocol Directional Control Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Berg Balance Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximally achievable dose (MAD) or maximum tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of composite events
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended phase 2 dose of exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Experiences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Months of Progression-free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: rate of failure under ceftaroline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of failure under ceftobiprole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asynchrony index (AI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Self-efficacy toward upright positions and mobility during labor
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Uncoupling protein 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pressure area distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: PCAT attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of EVP-6124 and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait Biomechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of ACOS in patients with COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to first contact with a cardiologist
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in markers for glucose intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Estrogen suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of mean flare values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain relief during post-tonsillectomy recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: evoked responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of days participants walked the recommended number of steps
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: proportion of days in the month participants walked 10,000 or more steps
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: number of consecutive weeks step goal met
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time within 3.9 and 10 mmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in emotional anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in somatic anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Bone Mineral Density (BMD) in HIP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Multifocal electroretinogram (mfERG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of major bleeding complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Hatched Eggs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of the TM among the LTCF staff
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Health care spending
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: IHC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate (CR and PR according to RECIST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of non-progressive disease at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite endpoint of death or major postoperative complications
Endpoint domain: Mortality/survival
Primary endpoint: Complete degradation of study product in the breast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: PAF metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stent encrustation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in gene array
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Executive skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Occurrence of at Least One Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Average Change in Oral Temperature From Baseline to Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Change in Systolic Blood Pressure From Baseline to Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Enteral protein intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total urine nitrogen excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PRU assayed by VerifyNow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nevirapine-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of device-specific inhaler technique errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic or pulmonary arterial thromboembolism
Endpoint domain: Mortality/survival
Primary endpoint: cutaneous temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of study participants colonized
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Gross Motor development
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fine Motor development
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adaptive living skills
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Adherence to the breathing exercise intervention
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Mean Visualization Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secondary AVF Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants With AVF Use for Hemodialysis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dynamic Hemodynamic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Who Retained on Tocilizumab Monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention Rate in Therapy, Percentage of Participants Achieving DAS 28 ESR <2.6 and <3.2 at Month 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Completed All Study Procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in 3-month plasma levels of APC-r
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in 3-month plasma levels of protein S
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in 3-month serum levels of SHBG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in 3-month serum levels of ethinyl estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in 3-month serum levels of DHEA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Caregiver grief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients with tumor fraction change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fractional excretion of sodium (FeNa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fever frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Plasma Potassium Levels after Rocuronium or Succinylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Plasma Potassium Levels after Sugammadex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Children's Depression Rating Scale, Revised (CDRS-R) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ki(cer) of [18F]DOPA PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of effective regurgitant orifice area (EROA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of women with any sperm in the cervical mucus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of women with ≥ 5 progressively motile sperm per high power field (HPF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Average number of progressively motile sperm per HPF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in hSBA geometric mean titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants achieving at least a four fold increase in hSBA titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants achieving a 'protective' hSBA titre of >1:4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of corticosteroid sparing control of ocular inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methylated status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change in quality of life (QOL) based on SNOT-22 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hernia-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Urinary excretion of modified nucleosides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rise in hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference in glucose measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of 100% Wound Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area under the concentration time curve from timepoint zero extrapolated to infinity (AUC-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Solicited Adverse Events (SEs) After Dose 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Adverse Events (AEs) After Dose 1
Endpoint domain: Adverse events/effects
Primary endpoint: necrotic cholecystitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: composite in-hospital adverse outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Major pathologic response (MPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to major adverse cardiac event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with reduced esophageal acid exposure during sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hospitalization for Cardiovascular/Pulmonary Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in the mean SBP at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the number of adverse events (AEs) post-infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Motor Score of ASIA scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of ACR 50 Criteria Responders at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Disease Activity Score (DAS) 28 During the Extension Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesics requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Detection of distant metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum peptide mass fingerprinting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Serum 17-OHP Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cmax of Fimasartan and Amlodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of Fimasartan and Amlodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal knee extensor (quadriceps) muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal knee flexor (hamstring) muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patellar tendon cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resection margin status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Subjects With Adverse Events as Determined by Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG
Endpoint domain: Adverse events/effects
Primary endpoint: Student Academic Vocabulary Knowledge in English
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Parent Academic Vocabulary Knowledge in Spanish
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Student Academic Vocabulary Usage in English
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Parent Academic Vocabulary Usage in Spanish
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning